# Resalis Therapeutics: Research, Turin, Italy

> Resalis Therapeutics: Resalis Therapeutics is a biopharmaceutical company based in Turin, Italy, founded in 2021. Based in Turin, Italy. Founded 2021.

Source: https://millionrounds.com/startup/resalis-therapeutics (Millionrounds; every figure on the page links to its filing or article)

Italy · [Research startup](https://millionrounds.com/companies)

# Resalis Therapeutics

Resalis Therapeutics is a biopharmaceutical company based in Turin, Italy, founded in 2021.

Email

Funding reported Last round: Series A

Research Turin, Italy

Follow Resalis Therapeutics and see its new rounds in your feed. [Start following](https://millionrounds.com/login?join=1&why=follow&next=%2Fstartup%2Fresalis-therapeutics)

Company summary

- **Founded:** 2021 5 years old
- **Team:** 12 11 to 50 people
- **Funding reported:** 26M as listed, currency not stated
- **Last round:** Series A Jan 2024

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for Resalis Therapeutics has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About Resalis Therapeutics

Resalis Therapeutics is a biopharmaceutical company based in Turin, Italy, founded in 2021.

The company specializes in developing non-coding RNA (ncRNA) therapeutics, particularly antisense oligonucleotides that target microRNAs. Resalis combines expertise in lipid metabolism and RNA modalities to create innovative solutions for complex metabolic disorders. The company is advancing its lead candidate, RES-010, which targets microRNA-22 to address obesity, metabolic-associated fatty liver disease, and liver inflammation. RES-010 is currently in a Phase II clinical trial, demonstrating promising results in preclinical studies. Resalis also offers services in drug discovery and life sciences, focusing on ncRNA drug modality development, antisense oligonucleotide design, and lipid metabolism research. With a commitment to addressing unmet medical needs, Resalis Therapeutics aims to provide effective, disease-modifying treatments for patients suffering from metabolic dysfunction and related conditions.

## What company datasets say Resalis Therapeutics raised

Funding, as reported

Reported in all **26M** in the source's currency

Rounds **3**

Last round **Series A**

Last round date **Jan 2024**

Investors listed **5**

## Founders and team

From Resalis Therapeutics's own website: 2 founders, 13 on the team.

**Riccardo Panella** Chief Scientific Officer & Co-Founder

**Sakari Kauppinen** Chief Technology Officer & Co-Founder

- **Alessandro Toniolo** Chief Executive Officer
- **Almut Nitsche** Chief Development Officer
- **Diana M. Røpcke** Chief Medical Officer
- **Thomas Eichinger** Chief Technical Development Officer
- **Anna Altieri** Translational Research Lead
- **Arianna Cuomo** Preclinical Research Associate
- **Claus Andersson** Non-Executive Director
- **Giulia Grillo** Preclinical Research Associate
- **Halina Novak** Non-Executive Director
- **Pietro Puglisi** Chairman
- **Sandor Batkai** Medical Director
- **Valentina Agnolon** Development Lead
- **Valentina Gaudio** Business Analyst

## On a portfolio page

Investors who name them

- [B-Engine](https://millionrounds.com/fund/b-engine)

Each firm lists Resalis Therapeutics on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

## The company, in detail

What they build

Known for

health care biotechnology research lipid metabolism rna mechanism of action metabolic diseases disease modification medical research metabolic health hospital & health care rna-based therapies antisense oligonucleotide medical obesity therapy microrna mir-22 phase 1 clinical trial therapeutic development

Built with from their website

WordPress.org Viewport Meta CookieYes Facebook SDK Priority Hints Google Font API Microsoft Exchange MySQL PrimeNG Microsoft 365 Apps & Services

+8 more

Mobile Friendly jQuery Aruba DNS RSS Facebook Social Plugins Aruba HTTP/3 Vimeo

- **Sector:** Research
- **Industry code:** NAICS 541714, SIC 2834, 8731
- **Region:** Piedmont
- **Revenue:** 1.5M a year, as listed
- **Full record:** [Every detail in the company directory](https://millionrounds.com/directory/resalis-therapeutics)

## Research in Italy

Startups like it

- [**Genespire** Milan · founded 2020](https://millionrounds.com/startup/genespire)
- [**Aptadir Therapeutics** Milano](https://millionrounds.com/startup/aptadir-therapeutics)
- [**Sibylla Biotech** Bresso · founded 2017](https://millionrounds.com/startup/sibylla-biotech)
- [**Algorithmiq** Milano · founded 2020](https://millionrounds.com/startup/algorithmiq)
- [**Phononic Vibes** Milan · founded 2018](https://millionrounds.com/startup/phononic-vibes-2)
- [**Contraria Biotech** Siena · founded 2017](https://millionrounds.com/startup/contraria-biotech)
- [**Cellply** Bologna · founded 2013](https://millionrounds.com/startup/cellply)
- [**Altheia Science** Milan · founded 2017](https://millionrounds.com/startup/altheia-science)

## Is this your company?

Add your raise, your deck and your story, and put Resalis Therapeutics in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)